These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25823619)

  • 1. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
    Descamps V; Helle F; Louandre C; Martin E; Brochot E; Izquierdo L; Fournier C; Hoffmann TW; Castelain S; Duverlie G; Galmiche A; François C
    Antiviral Res; 2015 Jun; 118():93-102. PubMed ID: 25823619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replication.
    Himmelsbach K; Hildt E
    Eur J Cell Biol; 2013 Jan; 92(1):12-20. PubMed ID: 23107224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication.
    Himmelsbach K; Sauter D; Baumert TF; Ludwig L; Blum HE; Hildt E
    Gut; 2009 Dec; 58(12):1644-53. PubMed ID: 19710032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
    Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
    Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.
    Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T
    Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins.
    Gao M; Duan H; Liu J; Zhang H; Wang X; Zhu M; Guo J; Zhao Z; Meng L; Peng Y
    Antiviral Res; 2014 Jun; 106():80-5. PubMed ID: 24680956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
    Kwon YC; Bose SK; Steele R; Meyer K; Di Bisceglie AM; Ray RB; Ray R
    J Virol; 2015 Nov; 89(22):11549-56. PubMed ID: 26355082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells.
    Liu S; Chen R; Hagedorn CH
    PLoS One; 2015; 10(7):e0131358. PubMed ID: 26186636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560].
    Ivashchenko AV; Iamanushkin PM; Mit'kin OD; Ezhova EV; Korzinov OM; Bulanova EA; Koriakova AG; Vyshemirskaia PV; Bychko VV; Ivashchenko AA
    Eksp Klin Farmakol; 2014; 77(10):38-43. PubMed ID: 25518527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
    Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
    Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
    Calland N; Sahuc ME; Belouzard S; Pène V; Bonnafous P; Mesalam AA; Deloison G; Descamps V; Sahpaz S; Wychowski C; Lambert O; Brodin P; Duverlie G; Meuleman P; Rosenberg AR; Dubuisson J; Rouillé Y; Séron K
    J Virol; 2015 Oct; 89(19):10053-63. PubMed ID: 26202241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
    Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
    J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro.
    Hang X; Peng H; Song H; Qi Z; Miao X; Xu W
    J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
    Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
    Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
    Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
    Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.
    Schaefer EA; Meixiong J; Mark C; Deik A; Motola DL; Fusco D; Yang A; Brisac C; Salloum S; Lin W; Clish CB; Peng LF; Chung RT
    World J Gastroenterol; 2016 Dec; 22(45):9954-9965. PubMed ID: 28018102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.